Vilon Petide (20mg)
At just two amino acids in length, Vilon is the shortest peptide known to have biological activity. Research shows that Vilon has potent anti-aging effects and that it is a powerful regulator of immune function. There is also good evidence that Vilon helps to regulate the vascular system and promotes hemostasis. Vilon has been shown to reduce the incidence and growth of spontaneous tumors, though its role as an adjuvant in cancer treatment (as opposed to prevention) has been called into question. Overall, Vilon has several staunch advocates, such as Dr. Vladimir Anisimov, who feel that the peptide is a useful geroprotective agent.
Vilon Review
Molecular Formula:Â C11H21N3O5
Molecular Weight:Â 257.30 g/mol
PubChem CID:Â 7010502
CAS No:Â 45234-02-4
Alternative Names:Â Lysylglutamate, normophthal, Lyslglutamic acid
Vilon peptide benefits
Research out of Russia indicates that Vilon is a potent regulator of chromatin structure. One study found that Vilon:
• induces unrolling of chromatin,
• activates synthetic processes via reactivation of ribosomal genes in the unrolled chromatin,
• releases repressed genes, and
• does not cause decondensation of pericentromeric structural chromatin[1].nduces unrolling of chromatin,
The net result of the changes that Vilon causes to DNA is reactivation of genes that are otherwise silenced. In general, chromatin is found in either the wound (heterochromatin) or unwound (euchromatin) states. Heterochromatin cannot be accessed by the apparatus that turns genes into proteins and thus functional components of the cell. Genes in these regions of DNA are simply unavailable for protein production.
In general, chromatin helps to regulate which genes are available for transcription and is thus one way that different-cells can have different functions or that the same cells can have different functions over time. Unfortunately, chromatin condensation is also something that occurs as a result of aging and senescence and is at least one reason why our cells and tissues lose function as we get older.
The ability of Vilon, and other peptide bioregulators, to reactivate certain genes by unraveling heterochromatin has been shown to restore immune function in elderly individuals. This effect is seen very clearly in lymphocytes. These white blood cells are responsible for antibody production and coordination of the immune response to both invading pathogens as well as diseases like cancer.
Similar to its activity in lymphocytes, Vilon has been shown to activate interluekin-2 signaling in cells of the spleen[3]. Interleukin-2 is important in coordinating the immune response to microbial infection and helps to prevent autoimmune reactions. By activating lymphocytes and splenocytes while boosting natural protection against autoimmune reactions, Vilon restores the immune system to a more active state and may even be useful in developing treatments for autoimmune diseases.
Adding to its ability to prevent autoimmune reactions is the role of Vilon in the thymus. Research in thymus cultures shows that Vilon increases the proliferation of CD5 T-cells. CD5 is a marker of mature T-helper cells as well as cytotoxic CD8 T-cells. The former helps to regulate the immune system and prevent autoimmune reactions, while the latter is one of the most potent anti-microbial cells in the body.
Interestingly, Vilon appears to only reactivate immune functions via genes that have been silenced by changes in chromatin. It does not appear to activate genes that would naturally be silent in the cells it affects. In other words, Vilon does not turn lymphocytes into neurons by activating genes that would normally not be active in healthy lymphocytes. Instead, the peptide appears to boost activity in the immune system while simultaneously helping to prevent autoimmune reactions.
Vilon Peptide and Cancer
As pointed out above, Vilon helps to reduce the incidence of cancer in mouse models, which is at least one way in which it prolongs average lifespan. Additional research shows that Vilon not only prevents tumors from forming, but inhibits their growth after they are present. This suggests that Vilon may be both an effective chemotherapeutic in its own right, as well as a potential additive to existing cancer treatments. In the future, Vilon may be a standard addition to everything from chemotherapy to radiation treatment and surgery.
At least one study, out of Russia, contradicts the claim that Vilon may be a useful adjuvant to chemotherapy. The works shows that the combination of Vilon and platinum-based chemotherapeutic agents is problematic rather than synergistic. Unfortunately, this study used only one specific type of chemotherapy and was limited in scope, so the results cannot be generalized. It remains to be seen if Vilon is only effective against cancer on its own or if the peptide can be added to other treatment regimens to boost results.
